A number of other analysts have also commented on COLL. TheStreet lowered Collegium Pharmaceutical from a b- rating to a c+ rating in a research note on Monday, April 11th. Needham & Company LLC increased their price objective on Collegium Pharmaceutical from $34.00 to $36.00 and gave the company a buy rating in a research note on Wednesday, April 6th. Zacks Investment Research lowered Collegium Pharmaceutical from a hold rating to a strong sell rating in a research note on Tuesday, April 26th. Cantor Fitzgerald raised Collegium Pharmaceutical from a neutral rating to an overweight rating and increased their price objective for the company from $18.00 to $26.00 in a research note on Tuesday, February 15th. Finally, HC Wainwright raised their price target on Collegium Pharmaceutical from $26.00 to $29.00 and gave the stock a buy rating in a research note on Tuesday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of Buy and a consensus price target of $31.00.
Collegium Pharmaceutical stock opened at $16.36 on Thursday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.76 and a current ratio of 0.97. The firm has a market capitalization of $554.98 million, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 0.16 and a beta of 1.07. Collegium Pharmaceutical has a fifty-two week low of $14.04 and a fifty-two week high of $25.66. The stock’s fifty day moving average is $17.85 and its two-hundred day moving average is $18.49.
Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Collegium Pharmaceutical by 126.3% in the 1st quarter. Royal Bank of Canada now owns 14,701 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 8,206 shares during the period. PDT Partners LLC purchased a new position in shares of Collegium Pharmaceutical in the 1st quarter worth about $301,000. Captrust Financial Advisors raised its holdings in shares of Collegium Pharmaceutical by 97.5% in the 1st quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock worth $44,000 after purchasing an additional 1,062 shares during the period. State Street Corp raised its holdings in shares of Collegium Pharmaceutical by 14.4% in the 1st quarter. State Street Corp now owns 1,308,167 shares of the specialty pharmaceutical company’s stock worth $26,634,000 after purchasing an additional 165,144 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Collegium Pharmaceutical by 1.1% in the 1st quarter. Invesco Ltd. now owns 1,010,612 shares of the specialty pharmaceutical company’s stock worth $20,576,000 after purchasing an additional 11,090 shares during the period.
Collegium Pharmaceutical Company Profile (Get Rating)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
- Get a free copy of the StockNews.com research report on Collegium Pharmaceutical (COLL)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.